莱茵生物
(002166)
| 流通市值：36.82亿 | | | 总市值：53.20亿 |
| 流通股本：5.14亿 | | | 总股本：7.42亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,493,929,546.69 | 888,977,405.17 | 512,171,633.28 | 252,624,843.19 |
| 营业收入 | 1,493,929,546.69 | 888,977,405.17 | 512,171,633.28 | 252,624,843.19 |
| 二、营业总成本 | 1,406,218,107.09 | 875,600,680.16 | 502,604,006.6 | 241,217,950.9 |
| 营业成本 | 1,129,187,821.45 | 684,720,224.22 | 387,416,432.33 | 193,559,495.1 |
| 税金及附加 | 10,442,792.9 | 6,539,380.75 | 4,360,352.3 | 538,129.63 |
| 销售费用 | 54,024,604.22 | 36,974,137.89 | 24,064,803.96 | 10,573,361.93 |
| 管理费用 | 139,748,302.56 | 97,565,995.18 | 58,660,782.19 | 20,804,934.45 |
| 研发费用 | 48,385,939.81 | 34,894,502.03 | 22,541,766.89 | 11,642,233.61 |
| 财务费用 | 24,428,646.15 | 14,906,440.09 | 5,559,868.93 | 4,099,796.18 |
| 其中:利息费用 | 32,901,228.59 | 27,679,205.1 | 14,442,288.09 | 6,102,083.16 |
| 其中:利息收入 | 7,894,233.33 | 11,285,827.78 | 7,880,631.77 | 4,488,187.94 |
| 加:公允价值变动收益 | 45,348,387.06 | 27,035,188.75 | 28,029,353.56 | 11,261,179.77 |
| 加:投资收益 | 4,827,738.46 | 5,467,431.91 | 5,761,029.69 | - |
| 资产处置收益 | -713,556.88 | -718,564.8 | -811,369.99 | -806,362.07 |
| 资产减值损失(新) | -44,290,289.27 | -1,781,638.52 | -1,042,032.8 | - |
| 信用减值损失(新) | 5,659,484.39 | 9,159,593.37 | 1,283,104.77 | 1,116,339.21 |
| 其他收益 | 19,778,163.88 | 12,334,493.19 | 10,423,557.55 | 3,244,106.28 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 118,321,367.24 | 64,873,228.91 | 53,211,269.46 | 26,222,155.48 |
| 加:营业外收入 | 227,862.65 | 79,520.62 | 72,393.44 | 49,380 |
| 减:营业外支出 | 2,186,646.53 | 1,353,269.09 | 899,053.15 | 448,000 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 116,362,583.36 | 63,599,480.44 | 52,384,609.75 | 25,823,535.48 |
| 减:所得税费用 | 18,016,580.9 | 10,477,852.12 | 8,920,125.72 | 3,076,703.13 |
| 六、净利润 | 98,346,002.46 | 53,121,628.32 | 43,464,484.03 | 22,746,832.35 |
| 持续经营净利润 | 98,346,002.46 | 53,121,628.32 | 43,464,484.03 | 22,746,832.35 |
| 归属于母公司股东的净利润 | 82,510,982.99 | 40,900,687.74 | 36,196,431.93 | 19,937,378.89 |
| 少数股东损益 | 15,835,019.47 | 12,220,940.58 | 7,268,052.1 | 2,809,453.46 |
| (一)基本每股收益 | 0.11 | 0.06 | 0.05 | 0.03 |
| (二)稀释每股收益 | 0.11 | 0.06 | 0.05 | 0.03 |
| 八、其他综合收益 | 14,162,932.96 | 20,300,263.42 | 22,965,737.34 | -9,436,927.37 |
| 归属于母公司股东的其他综合收益 | 14,162,932.96 | 20,300,263.42 | 22,965,737.34 | -9,436,927.37 |
| 九、综合收益总额 | 112,508,935.42 | 73,421,891.74 | 66,430,221.37 | 13,309,904.98 |
| 归属于母公司股东的综合收益总额 | 96,673,915.95 | 61,200,951.16 | 59,162,169.27 | 10,500,451.52 |
| 归属于少数股东的综合收益总额 | 15,835,019.47 | 12,220,940.58 | 7,268,052.1 | 2,809,453.46 |
| 公告日期 | 2024-04-10 | 2023-10-27 | 2023-08-26 | 2023-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |